Verkazia is EU approved to treat severe vernal keratoconjunctivitis .- Santen Pharma.
Santen Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing approval for DE-076C (Verkazia eye drop emulsion containing 0.1% (1mg/ml) ciclosporin, hereafter Verkazia) as an orphan medicinal product.
Verkazia is indicated for treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. Santen has been highly committed to developing this important new orphan medicinal product for children suffering this distressing and chronically debilitating condition that has rare disease status in Europe.
VKC is a severe and recurrent allergic eye condition, which predominantly affects children (mainly boys) and young adults. The condition is characterised by severe inflammation of the eye surface, including the conjunctiva and cornea. VKC results in intense itching, photophobia, painful eyes and even potential permanent loss of vision. No other comparable treatment has been licensed by the EMA. Thus, Verkazia is considered to have a significant benefit to those affected by this condition.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins